Mobia Medical Announces Addition of Paired VNS to Updated AHA Stroke Guidelines

AUSTIN, Texas, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that implantable paired Vagus Nerve Stimulation (VNS) has been recognized in the 2026 Guideline for Adult Stroke Rehabilitation and Recovery: A Guideline From the American Heart Association (AHA) and American Stroke Association (ASA) (link), published August 27, 2026 in Stroke as a treatment option to improve upper-limb function and impairment for chronic stroke survivors.

The new guideline states that VNS paired with high-dose task-specific training may be considered to improve upper-limb function and impairment for eligible patients. Mobia Medical’s Vivistim(®) Paired VNS™ System is the only FDA-approved system that delivers this treatment approach.